All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2017; the latest 2025-03-05.
From the record
Xenon Pharmaceuticals Inc.'s filings since 2017 show 1 warning event: an auditor change (8-K item 4.01, the latest 2025-03-05) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+1.6% a year over 7 filed years; profitable in 0 of 7.
From the record
Xenon Pharmaceuticals Inc.'s 7 filed years say what it did: revenue went from $7 million in fiscal 2019 to $8 million in fiscal 2025, up 1.6% a year; it rose in 1 of 4 years; the deepest fall was 100% from fiscal 2020 to fiscal 2023; net income was positive in 0 of 7 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 6.6/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Xenon Pharmaceuticals Inc.'s shareholder treatment is put at 6.6 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 34% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -59%: lost 59¢ per shareholder dollar. Leverage 8%: owes 8¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Xenon Pharmaceuticals Inc. lost about 59 cents for every dollar of shareholders' money. Leverage: it owed about 8 cents per dollar of assets, and net share issuance: its share count grew 1.7% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 27% of 315 in its family; net margin -4612.1%.
From the record
Xenon Pharmaceuticals Inc.'s standing among 315 graded names in its industry family: revenue of $8 million in fiscal 2025 ranks in the bottom 38% by size; a net margin of -4612.1% ranks in the bottom 16%; revenue growth of -7.4% a year over the last 3 filed years ranks in the bottom 28% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
bottom 40% of 315 in its family for leadership; chief executive since 2021.
From the record
Xenon Pharmaceuticals Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Mortimer, Ian (PRESIDENT & CEO, as filed), filing under that title since 2021-06-03, 5.4 years (top 45% of its family); the 12 officers and directors filing in the last fifteen months have been on the record a median of 5.3 years (bottom 42%); 9 officer or director changes were reported on Form 8-K since 2023-11-13, against the 12 people in charge now (bottom 23%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
top 48% of 273 in its family for room to expand.
From the record
Xenon Pharmaceuticals Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $199 million against no long-term debt tagged leaves 31.5% of its assets as net cash, top 46% of its family; cash from operations less capital spending is -3732.2% of revenue (bottom 13%); research spending of 4012.5% of revenue (top 11%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 47% of 306 in its family for growth drivers.
From the record
Xenon Pharmaceuticals Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -7.4% a year over the last three filed years against 1.6% over all 7, slowing (bottom 37% of its family); research spending grew 41.7% a year (top 11%); capital spending grew -34.9% a year (bottom 33%) (its annual reports). Xenon Pharmaceuticals Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
SI estimate 1.6/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Xenon Pharmaceuticals Inc.'s expectations vs reality is put at 1.6 of 10 with a confidence of 35 of 100, because read from one part only, net income against the prior three years' average, which ranks in the bottom 16% of 284 in its family; the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change. A filing that carries the missing parts replaces this estimate with the filed reading.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made